lifestyle.marketresearchjournals.com

Author: FibroBiologics, Inc.

FibroBiologics Announces Closing of $3 Million Public Offering

April 2, 2026
FibroBiologics Announces Pricing of $3 Million Public Offering

March 31, 2026
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial

March 31, 2026
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement

March 25, 2026
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

March 12, 2026
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

March 5, 2026
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

March 2, 2026
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update

February 24, 2026
FibroBiologics Granted Extension by Nasdaq to Regain Compliance

February 23, 2026
FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University

February 12, 2026